ARTICLE SUMMARY:
On a panel at MedTech Strategist’s Innovation Summit in Dublin, seasoned venture capitalists gave us their take on the abysmal medtech investment statistics for 2023 and what strategies they dictate for companies looking for funding and for their own funds going forward.
Each year, at MedTech Strategist’s Innovation Summit in Dublin, we present “MedTech by the Numbers,” a panel session where we ask VCs to identify trends inherent in the previous year’s investment and M&A activity. At this year’s summit in April, Jennifer McMahon presided over the panel. A partner at Seroba, which invests in biotech and medtech with a main concentration in Europe (and with a reach to North America), McMahon brought together four VCs with different perspectives, although all invest in medtech to some degree.
